Iktos and SRI Collaborate to Accelerate Discovery and Development of Novel Anti-Viral Therapies

 Iktos and SRI Collaborate to Accelerate Discovery and Development of Novel Anti-Viral Therapies

Iktos and SRI Collaborate to Accelerate Discovery and Development of Novel Anti-Viral Therapies

Shots:

  • The collaboration will combine Iktos’ generative modeling AI technology with SRI’s SynFini synthetic chemistry platform to develop optimized compound & to facilitate the identification of drug therapies treating multiple viruses, including influenza and COVID-19
  • Iktos’AI technology is based on deep generative models that speed up the drug discovery process by automatically designing virtual novel molecules having desirable characteristics of a novel drug therapies
  • SRI’s SynFini platform is designed to accelerate discovery and development by automating the design, RSO and production of target molecules. The collaboration demonstrates a new paradigm in rapid discovery against pharmaceutical targets

Click here ­to­ read full press release/ article | Ref: SRI | Image: Iktos

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post